This is a news story, published by Ars Technica, that relates primarily to Lykos news.
For more Lykos news, you can click here:
more Lykos newsFor more mental health treatments news, you can click here:
more mental health treatments newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
FDA investigators. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest MDMA trials news, FDA rejection news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDA reviewArs Technica
•
78% Informative
The FDA is reportedly expanding an investigation into the clinical trials behind MDMA therapy.
The FDA rejected the MDMA therapy for PTSD earlier this month .
The company behind the therapy, Lykos , says it's laying off 75 percent of its staff and overhauling its leadership.
A Wall Street Journal report says four additional people have been interviewed by the FDA .
VR Score
76
Informative language
76
Neutral language
8
Article tone
formal
Language
English
Language complexity
74
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Source diversity
5
Affiliate links
no affiliate links